Cogent’s Bezuclastinib Gains FDA Priority Review for GIST
WALTHAM, Mass. and BOULDER, Colo., May 28, 2026 Cogent Biosciences has announced a major regulatory milestone with the U.S....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
WALTHAM, Mass. and BOULDER, Colo., May 28, 2026 Cogent Biosciences has announced a major regulatory milestone with the U.S....
TOKYO, Feb. 13, 2026 — Nxera Pharma Co., Ltd. reported its consolidated financial and operational results for FY2025, outlining...
SuZhou, China – Nov. 24, 2025 — Innovent Biologics (01801.HK), a leading Chinese biopharmaceutical company focused on oncology, cardiovascular/metabolic,...
BRIDGEWATER, N.J., and BENGALURU, India – October 16, 2025: Biocon Biologics Ltd., a global leader in biosimilars, has expanded...
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
EAST HANOVER, N.J., Sept. 30, 2025 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has...
